Clinical trials: CEACAM5
Solid Tumors, Colorectal Cancer
Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors
The purpose of this study is to evaluate the safety and early clinical activity of M9140 in Chinese participants with locally advanced or metastatic colorectal cancer (CRC).
- Trial name
- NCT06806046
- Testing
- M9140
- Where
- 3 sites in China
- Volunteers
- 12 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Gastrointestinal Adenocarcinomas
A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas
To determine the maximum tolerated dose and/or optimum biologic dose of MEDI-565 in adult subjects and evaluate the safety profile in adult subjects with advanced gastrointestinal adenocarcinomas who have no available standard or…
- Trial name
- NCT01284231
- Testing
- MEDI-565
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- MedImmune LLC
Colorectal Cancer, Esophageal Cancer
Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of two different vaccines in treating patients who have cancer of the…
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00012246
- Testing
- carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- The University of Texas Medical Branch, Galveston
the Relationship Between the Tumor Markers and Interstitial Lung Disease Patients
The Relationship Between the Tumor Markers and Interstitial Lung Disease
The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA125 are often increased in interstitial lung disease patients.
- Trial name
- NCT04597814
- Testing
- No Intervention
- Where
- China
- Volunteers
- 13 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Colorectal Cancer, Metastatic Cancer
Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer
RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build an immune response to kill their tumor cells.
- Trial name
- NCT00003433
- Testing
- carcinoembryonic antigen RNA-pulsed DC cancer vaccine
- Where
- United States
- Sponsor
- Duke Cancer Institute
Colorectal Cancer
To Explore the Effect of Huaier Granule on the Negative Conversion Rate After the CEA Level Increases Again After Colorectal Cancer Surgery
This study is a prospective, observational and exploratory study to explore the effect of Huaier Granule on the negative conversion rate of patients with increased CEA levels after colorectal cancer surgery.
- Trial name
- NCT06665334
- Testing
- Huaier granule
- Volunteers
- 134 people
- Sponsor
- Fudan University
Solid Tumors, Gastric Cancer
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study.
- Conditions
- Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
- Trial name
- NCT06710132
- Testing
- M9140
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 184 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Colorectal Cancer
Feasibility, Reliability, and Satisfaction of CEA Using Home Based (Automated) Capillary Blood Sampling
The goal of this study is to determine the feasibility of CEA assessments at home using (automated) capillary sampling in patients in the follow-up after treatment for colorectal cancer.
- Trial name
- CASA-I (NCT05646030)
- Testing
- TAP-II, Lancet capillary sampling, Venipuncture
- Where
- Netherlands
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Colorectal Cancer, Liver Metastases
Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. As such they are currently used in clinical vaccination protocols in cancer patients.
- Trial name
- NCT00228189
- Testing
- CEA-loaded dendritic cell vaccine
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Liver Metastases
CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer
This is an open label, fixed dose, phase Ib trial of anti-CEA CAR-T cell infusions delivered via the hepatic artery or splenic vein using the Surefire Infusion System (SIS) for patients with CEA-expressing liver metastases or…
- Trial name
- HITM-SURE (NCT02850536)
- Testing
- anti-CEA CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Roger Williams Medical Center
Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
Primary Objective: For Cohort A, Cohort B, and Cohort C Part 2: To assess the antitumor activity of tusamitamab ravtansine in metastatic breast cancer (mBC) and tusamitamab ravtansine monotherapy and in combination with…
- Trial name
- CARMEN-BT01 (NCT04659603)
- Testing
- tusamitamab ravtansine, Gemcitabine
- Where
- 29 sites in United States, Argentina and 8 more
- Volunteers
- 50 people
- Sponsor
- Sanofi
Colorectal Cancer, Metastatic Colon Cancer
SGM-101 in Colorectal Lung Metastases
Near-infrared fluorescence-guided oncologic surgery (FGOS) with the use of a tumor specific tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about tumor location and extensiveness.
- Trial name
- SGM-CLM (NCT04737213)
- Testing
- SGM-101
- Where
- 2 sites in Netherlands
- Volunteers
- 10 people
- Sponsor
- Leiden University Medical Center
Colorectal Cancer
Immunoscintigraphy Using Radiolabeled Monoclonal Antibody in Finding Tumor Cells in Patients With Colorectal Cancer
RATIONALE: Diagnostic procedures, such as immunoscintigraphy, using a radiolabeled monoclonal antibody may help find and diagnose colorectal cancer.
- Trial name
- NCT00647153
- Testing
- pharmacological study, single photon emission computed tomography, iodine I 123 anti-CEA recombinant diabody T84.66
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Solid Tumors
A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety, tolerability and preliminary efficacy of KIVU-305, a CEACAM5-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid…
- Trial name
- NCT07545356
- Testing
- KIVU-305
- Where
- 3 sites in Australia
- Volunteers
- 76 people
- Sponsor
- Kivu Bioscience Inc.
Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic…
- Conditions
- Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer
- Trial name
- DUO-CRC-NK-111 (NCT07589517)
- Testing
- EB-DUO-CAR-NK-CEA/GCC, Lymphodepletion
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Biotech
Metastatic Lung Cancer, Metastatic Breast Cancer
INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701
This study is a prospective, open-label, multi-cohort, exploratory phase II clinical trial in patients with either CEACAM5-positive NSQ NSCLC, ER+ breast cancer or gastric cancer.
- Conditions
- Metastatic Lung Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer
- Trial name
- INTRUSION (NCT05703555)
- Testing
- Tusamitamab ravtansine
- Where
- Netherlands
- Sponsor
- Erasmus Medical Center
Colorectal Cancer, Colorectal Adenocarcinoma
Stage II/III Colorectal Cancer Recurrence
This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.
- Conditions
- Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage III
- Trial name
- CENSURE (NCT06314958)
- Testing
- CENSURE
- Where
- 4 sites in United States, China and 1 more
- Volunteers
- 400 people
- Sponsor
- City of Hope Medical Center
Metastatic Colorectal Cancer
Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
This is an open-label, multicenter, Phase Ib study to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) in the weekly (QW) and/or every 3 weeks (Q3W) regimens, safety, tolerability, PK…
- Trial name
- NCT04826003
- Testing
- RO7122290, Cibisatamab, Obinutuzumab
- Where
- 13 sites in Denmark, Netherlands and 3 more
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8
An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
This early phase I trial investigates how well 64Cu-labeled M5A antibody scan works in assessing tumor activity before and after patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced) who…
- Conditions
- Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8
- Trial name
- NCT05245786
- Testing
- Copper Cu 64 Anti-CEA Monoclonal Antibody M5A, Imaging Technique
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center